Results 61 to 70 of about 982 (100)

Repeated cycles of peptide receptor radionuclide therapy (PRRT) – Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET

Radiotherapy and Oncology, 2012
PRRT is a known tool in the management of patients with disseminated and inoperable NETs. The aim of study was to assess the effectiveness of the repeated cycles of PRRT in patients with disseminated and inoperable NETs.Eighty nine patients were included in the PRRT.
Dorota, Pach, Anna, Sowa-Staszczak, Jolanta, Kunikowska, Leszek, Królicki, Małgorzata, Trofimiuk, Agnieszka, Stefańska, Monika, Tomaszuk, Bogusław, Głowa, Renata, Mikołajczak, Dariusz, Pawlak, Agata, Jabrocka-Hybel, Alicja B, Hubalewska-Dydejczyk   +11 more
openaire   +2 more sources

[A Report on Health Resource Use in Internal Radiation Therapy Using 177Lu-DOTA-TATE].

Kaku igaku. The Japanese journal of nuclear medicine, 2021
Internal radiation therapy using lutetium-177(177Lu)-DOTA-TATE injection will be applied in actual clinical practice soon. However, the NHI medical technical fee for the use of 177Lu-DOTA-TATE injection has not yet been set. The Japanese Society of Nuclear Medicine surveyed health resource use in internal radiation therapy using 177Lu via ...
Katsuhiko, Kato, Soichi, Nakamura, Yoshinori, Matoba, Seigo, Kinuya   +3 more
openaire   +1 more source

‘Reverse discordance’ between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan

Nuclear Medicine Communications, 2011
In this technical note, an unusual discordance between diagnostic and posttherapeutic scan resulting from the use of different somatostatin receptor ligands in two settings is described. Such observation, we believe, is multifactorial, but most importantly arises due to different receptor affinity profile of the ligands and different somatostatin ...
Sandip, Basu, Amit, Abhyankar, Purushottam, Kand, Rakesh, Kumar, Ramesh, Asopa, Mysore Govinda Ramakrishna, Rajan, Uday, Nayak, Hemant, Shimpi, Tapas, Das, Meera, Venkatesh, Sudipta, Chakrabarty, Sharmila, Banerjee   +11 more
openaire   +2 more sources

The Effectiveness of 177Lu-DOTA TATE in Radioiodine-Refractory Differentiated Thyroid Cancer

2020
[No Abstract Available]
Nazari, A., Sager, M. S., Bilgic, S., Beytur, F., Besli, R. L. Uslu, Asa, S., Sonmezoglu, K.   +6 more
openaire   +1 more source

Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use ¹⁷⁷ Lu-DOTA-TATE: The Intricate Radiochemistry Aspects

Cancer Biotherapy and Radiopharmaceuticals, 2017
177Lu-DOTA-TATE is a clinically useful and promising therapeutic radiopharmaceutical for peptide receptor radionuclide therapy of neuroendocrine tumors (NETs) overexpressing somatostatin receptors. Currently, the radiopharmaceutical is prepared in-house at nuclear medicine centers, thereby restricting its use to limited centers only.
Anupam, Mathur, Vrinda, Prashant, Navin, Sakhare, Sudipta, Chakraborty, K V, Vimalnath, Repaka Krishna, Mohan, Chanda, Arjun, Barkha, Karkhanis, Ravi, Seshan, Sandip, Basu, Aruna, Korde, Sharmila, Banerjee, Ashutosh, Dash, Satbir Singh, Sachdev   +13 more
openaire   +2 more sources

Results of Individual Patient Dosimetry in Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu DOTA-TATE and ¹⁷⁷ Lu DOTA-NOC

Cancer Biotherapy and Radiopharmaceuticals, 2007
One of the few treatment options for inoperable neuroendocrine tumors (NET) is peptide receptor radiotherapy with somatostatin analogs. In this study, we compared the dosimetric parameter uptake, half-life (kinetics), and mean absorbed organ and tumor doses of (177)Lu DOTA-NOC and (177)Lu DOTA-TATE.Ninety-five (95) post-therapeutic dosimetric ...
Christiane, Wehrmann, Stefan, Senftleben, Carolin, Zachert, Dirk, Müller, Richard P, Baum   +4 more
openaire   +2 more sources

Peptide-receptor radionuclide therapy of 177Lu-DOTA-TATE progressive medullary thyroid cancer. foreign and domestic experience: a review

Diagnostic radiology and radiotherapy
Introduction : Medullary thyroid cancer is a rare neuroendocrine tumor and occurs in hereditary and sporadic forms. As in other NETs, somatostatin receptors are overexpressed in the cell membrane in more than 75% of cases of medullary thyroid cancer. Therefore, in recent years, radioactively labeled somatostatin
E. V. Borodavina, M. А. Sigov, A. Yu. Shurinov, S. I. Kutukova, V. V. Krylov   +4 more
openaire   +1 more source

PRRT 177Lu-DOTA-TATE in pancreatic neuroendocrine tumors - When to initiate?

Endocrine Abstracts, 2023
Sara Franco, Sampaio Ines Lucena, Goncalo Ferreira, Daniel Barbosa, Sara Gil-Santos, Luiz Henrique Vara, Santos Ana Paula, Isabel Torres, Hugo Duarte   +8 more
openaire   +1 more source

177Lu-DOTA-TATE therapy in patients with NETs: Toxicity, response and prognostic indicators

2014
[No abstract available]
Demirci, E., Ocak, M., Kabasakal, L., Aygun, A., Araman, A., Uslu, I.   +5 more
openaire   +1 more source

Postmarketing safety surveillance of 177Lu-DOTA-TATE (LUTATHERA): an observational, pharmacovigilance study leveraging FAERS database

Nuclear Medicine Communications
Objective 177 Lu-DOTA-TATE (LUTATHERA) is a crucial radiopharmaceutical in neuroendocrine tumor therapy, yet real-world long-term safety data across diverse populations remain limited.
Xinhua Wu, Jing Liao, Wei Chen, Jianwei Dou   +3 more
openaire   +2 more sources